PEAK6
MDGL icon

PEAK6’s Madrigal Pharmaceuticals MDGL Stock Holding History

PEAK6’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$209K Hold
400
– – ﹤0.01% 2266
2025
Q4 		$233K Buy
+400
New +$204K ﹤0.01% 2345
2025
Q1 		– Sell
-7,500
Closed -$2.31M – 3367
2024
Q4 		$2.31M Buy
+7,500
New +$2.11M ﹤0.01% 1329

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PEAK6's MDGL Position: Q1 2026 in Review

PEAK6 reduced its Madrigal Pharmaceuticals (MDGL) stake by 97% in Q1 2026, selling an estimated $35.8K and leaving 2 shares worth $1.14K. The position accounts for ﹤0.01% of the portfolio, ranked #2589.

PEAK6 first reported a position in MDGL in Q4 2024 and has held it in 3 quarters since. The position peaked at $710K in Q4 2024. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • PEAK6 held 2 shares of Madrigal Pharmaceuticals worth $1.14K as of Q1 2026.
  • PEAK6 sold 75 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $35.8K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of PEAK6's portfolio in Q1 2026, its #2589 holding.
  • PEAK6 first reported a position in Madrigal Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • PEAK6's Madrigal Pharmaceuticals position peaked at $710K in Q4 2024.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on PEAK6's 13F filing for Q1 2026, filed 14 May 2026.